Literature DB >> 16581037

Mice with mutations in the HPA-system as models for symptoms of depression.

Marianne B Müller1, Florian Holsboer.   

Abstract

Genetically engineered mice hold promise to help us understand the effects of enhanced or reduced gene activity upon behavior and metabolism. Because many basic and clinical studies suggest that alterations of the hypothalamic pituitary adrenocortical (HPA) system are involved in the development and course of depression, mouse mutants with genetic modifications of genes regulating the HPA system were generated. This review summarizes these effects and concludes that advanced technologies allowing for regional overexpression or inactivation of genes or introduction of polymorphisms into the mouse genome are well suited to explain individual symptoms or symptom patterns prevalent among depressives. However, as depression is a complex disorder in which minor changes of many genes as well as environmental factors (including epigenetic programming) play a causal role and determine the phenotype, the use of mice with single gene mutations needs to be critically discussed when attempting to create a genetic animal model of depression.

Entities:  

Mesh:

Year:  2006        PMID: 16581037     DOI: 10.1016/j.biopsych.2006.02.008

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  21 in total

Review 1.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

Review 2.  Glucocorticoid receptor signaling in health and disease.

Authors:  Mahita Kadmiel; John A Cidlowski
Journal:  Trends Pharmacol Sci       Date:  2013-08-14       Impact factor: 14.819

3.  Animal models of depression: molecular perspectives.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Curr Top Behav Neurosci       Date:  2011

4.  Forebrain glutamatergic, but not GABAergic, neurons mediate anxiogenic effects of the glucocorticoid receptor.

Authors:  J Hartmann; N Dedic; M L Pöhlmann; A Häusl; H Karst; C Engelhardt; S Westerholz; K V Wagner; C Labermaier; L Hoeijmakers; M Kertokarijo; A Chen; M Joëls; J M Deussing; M V Schmidt
Journal:  Mol Psychiatry       Date:  2016-05-31       Impact factor: 15.992

Review 5.  Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease.

Authors:  J M Goldstein; R J Handa; S A Tobet
Journal:  Front Neuroendocrinol       Date:  2013-12-16       Impact factor: 8.606

Review 6.  Animal models for depression associated with HIV-1 infection.

Authors:  Isabella Cristina Gomes Barreto; Patricia Viegas; Edward B Ziff; Elisabete Castelon Konkiewitz
Journal:  J Neuroimmune Pharmacol       Date:  2013-12-12       Impact factor: 4.147

7.  Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways.

Authors:  Yaoyang Zhang; Michaela D Filiou; Stefan Reckow; Philipp Gormanns; Giuseppina Maccarrone; Melanie S Kessler; Elisabeth Frank; Boris Hambsch; Florian Holsboer; Rainer Landgraf; Christoph W Turck
Journal:  Mol Cell Proteomics       Date:  2011-08-23       Impact factor: 5.911

8.  Magnetic brain stimulation using iron oxide nanoparticle-mediated selective treatment of the left prelimbic cortex as a novel strategy to rapidly improve depressive-like symptoms in mice.

Authors:  Qing-Bo Lu; Jian-Fei Sun; Qu-Yang Yang; Wen-Wen Cai; Meng-Qin Xia; Fang-Fang Wu; Ning Gu; Zhi-Jun Zhang
Journal:  Zool Res       Date:  2020-07-18

Review 9.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 10.  A final common pathway for depression? Progress toward a general conceptual framework.

Authors:  Eric A Stone; Yan Lin; David Quartermain
Journal:  Neurosci Biobehav Rev       Date:  2007-10-10       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.